Faculty: Yaron Finkelstein, MD
Associate Professor, Pediatrics and Pharmacology & Toxicology
General Research Areas: Pediatric Toxicology; Cancer and Hematology Drugs in Children; Neuropharmacology.
Dr. Finkelstein’s main research focus is in pediatric therapeutics in acute-care settings. His long-term goal is optimization of drug safety, especially of highly toxic drugs and poisoning management and prevention in children. Using cutting-edge methodologies in pharmacogenetics, pharmacometrics, adverse drug-reaction analysis, translational research and epidemiological/toxico-surveillance tools he strives to enhance effective and safe drug delivery to children with an emphasis on emergency settings. Dr. Finkelstein has also made significant contributions to the understanding and prevention of pediatric poisonings, accidental and deliberate.
Dr. Finkelstein has published over 100 original and review articles in peer-reviewed journals, as well as book chapters in leading medical textbooks; he sits on scientific journals’ editorial boards and has an active role in various professional societies, such as the American College of Medical Toxicology. Dr. Finkelstein holds international scientific awards, and his research program is supported by local and international grants.
Y Finkelstein, J R Hutson, P Wax, J Brent. Toxico-Surveillance of infant and Toddler poisoning in the United States: use of the Toxicology Investigators Consortium (ToxIC) Registry. J Med Toxicol 2012 April 20 [Epub ahead of print].
JR Hutson, S. Weitzman, T. Schechter, RJ. Arceci, RB Kim, Y Finkelstein. Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants. Exp Opin Drug Metab Toxicol. 2012 June 8(6): 709-22.
Y Finkelstein, T. Schechter, SB. Freedman. Surgical masks vs N95 respirators for preventing influenza. JAMA Mar 10:303(10):938, 2010.
T Schechter, Y Finkelstein, A Lim, W Kahr, S Williams, AL Chan, G Deveber, LR Brandao. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored by Anti-Xa levels. J Thromb Hemost. 2012 Mar;10(3):368-74.
T Schechter, A Kirton, S Laughlin, AM Pontigon, Y Finkelstein, D Macgregor, A Chan, G Deveber, LR Brandão. Safety of anticoagulants in children with arterial ischemic stroke. Blood. 2012 Jan 26;119(4):949-56.
S. Weitzman, Y Finkelstein, R. Arceci. Neonatal Cancer. In: Rudolph CD, Rudolph AM, Hostetter MK, Lister GE, Siegel NJ.
eds: Rudolph’s Textbook of Pediatrics, 22nd Ed. New York, McGraw-Hill, Section 24 – Neoplastic Disorders, Chapter 447, pp1614-19, Feb 2011.
D Lin, JA Seabrook, DM Matsui, SM King, MJ Rieder, Y Finkelstein. Palatability, Adherence and Prescribing Patterns of Antiretroviral Drugs for Children with Human Immunodeficiency Virus Infection in Canada. Pharmacoepidemiology and Drug Safety. 2011 Dec, 20(12): 1246-52.
Y Finkelstein, G Soon, P Acuna, M George, E Pope, S Ito, N Shear, G Koren, MW Shannon, F Garcia-Bournissen. Recurrence and Long-term Outcome of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children. Pediatrics. 2011,128:4; pp 723-28.
G. Dubnov, Juurlink DN, R Fogelman, P Merlob, Ito S, G Koren, Y. Finkelstein. Antenatal use of Selective Serotonin Reuptake Inhibitors and Qt Interval Prolongation in Newborns. Pediatrics 122:e710-715, 2008.
Hospital For Sick Children
Division of Clinical Pharmacology and Toxicology
525 University Avenue